Proper study design is one of the most important aspects of successful biomarker discovery and that includes both a thorough understanding of the disease population and which statistical tools to use. New research from Arizona State University examines how the predictive reliability of statistical tests relies not only on the choice of the test (clearly) […]
Research published in the British Journal of Cancer correlates membranous expression of PODXL in urothelial bladder cancer with unfavorable tumor characteristics. The marker demonstrates potential clinical utility for improved treatment stratification of patients.
A study conducted by Dr. Eric Thorin of the Montreal Heart Institute, suggests blood levels of angiopoietin-like protein 2 (angptl2) may represent an early biomarker for atherosclerosis. Researchers discovered levels of angptl2 are six times higher in mice with coronary heart disease than in healthy mice. Their study also revealed angptl2 levels increase with age […]
Download this webinar to learn how Myriad RBM’s products and services were used by VentiRx to compare potency, define PK/PD relationships, identify potential clinical biomarkers of VTX-2337 activity and establish a Minimal Anticipated Biological Effect Level (MABEL) for the initial clinical trial.
A study presented at this month’s American Association for Cancer Research annual meeting by Jose Baselga, M.D., Ph.D., suggests that tumor levels of HER2 may determine the patient’s response to treatment with T-DM1. Patients with tumors expressing higher levels of HER2 gained greater benefits from T-DM1 compared to patients with tumors expressing lower levels of […]
Migraines, severe headaches that last for greater than four hours, are often characterized by specific symptoms such as nausea, sensitivity to light and sound, and throbbing pain. More than 30 million Americans suffer from migraines, mostly women, yet their origins remain unclear. Now, researchers at Johns Hopkins University have identified adiponectin (ADP) as a marker […]
Researchers identified a 3-biomarker immunoassay, measuring NNMT, LCP1, and NM23A, that successfully distinguishes healthy patients from those with renal cell carcinoma (RCC). If their results can be validated, physicians would have an unprecedented tool for the early detection and subsequent treatment of this silent and deadly disease.
Less than two hundred years ago schizophrenia emerged from a tangle of mental disorders known simply as madness. Today its diagnosis remains shrouded in ambiguity. Psychiatrists may discover that this disorder is not a single syndrome after all but a bundle of overlapping conditions. The highlighted research is from Myriad RBM’s collaboration with Sabine Bahn’s […]
A recent article featuring Myriad RBM’s services was published in PLoS ONE by a group of researchers investigating the differences in biomarker profiles between men and women. The group measured 174 proteins across nine independent groups, with 196 males and 196 females. As would be expected, clusters of molecules with distinct biological roles, such as […]
There is mounting evidence that systemic inflammation is involved in depression and now a recent article in JAMA Psychiatry supports this hypothesis. Danish researchers looked at data from two broad population studies with a total of more than 73,000 individuals and found that elevated levels of CRP were commonly found in depressed patients. While the […]